Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
- PMID: 1863023
- DOI: 10.7326/0003-4819-115-5-343
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
Abstract
Objective: To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival.
Design: Registry with prospective follow-up.
Setting: Thirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute.
Patients: Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988.
Measurements: At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals.
Main results: The estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DLCO). Drug therapy at entry or discharge was not associated with survival duration.
Conclusions: Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.
Similar articles
-
Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25. Circulation. 2018. PMID: 29070502 Clinical Trial.
-
Survival in primary pulmonary hypertension. Validation of a prognostic equation.Circulation. 1994 Apr;89(4):1733-44. doi: 10.1161/01.cir.89.4.1733. Circulation. 1994. PMID: 8149539
-
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.J Am Coll Cardiol. 2002 Aug 21;40(4):780-8. doi: 10.1016/s0735-1097(02)02012-0. J Am Coll Cardiol. 2002. PMID: 12204511 Clinical Trial.
-
Graded balloon atrial septostomy in severe pulmonary hypertension.Indian Heart J. 2002 Mar-Apr;54(2):164-9. Indian Heart J. 2002. PMID: 12086379 Review.
-
Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature.Medicine (Baltimore). 2007 Sep;86(5):299-315. doi: 10.1097/MD.0b013e3181579781. Medicine (Baltimore). 2007. PMID: 17873760 Review.
Cited by
-
Selenium supplementation elevated SELENBP1 to inhibit fibroblast activation in pulmonary arterial hypertension.iScience. 2024 Sep 26;27(10):111036. doi: 10.1016/j.isci.2024.111036. eCollection 2024 Oct 18. iScience. 2024. PMID: 39435142 Free PMC article.
-
Novel therapeutic approaches to preserve the right ventricle.Curr Heart Fail Rep. 2013 Mar;10(1):12-7. doi: 10.1007/s11897-012-0119-3. Curr Heart Fail Rep. 2013. PMID: 23065390 Free PMC article. Review.
-
Pulmonary arterial banding in mice may be a suitable model for studies on ventricular mechanics in pediatric pulmonary arterial hypertension.J Cardiovasc Magn Reson. 2021 Jun 3;23(1):66. doi: 10.1186/s12968-021-00759-8. J Cardiovasc Magn Reson. 2021. PMID: 34078382 Free PMC article.
-
Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.Front Cardiovasc Med. 2022 Sep 20;9:991586. doi: 10.3389/fcvm.2022.991586. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36204579 Free PMC article.
-
Role of Hypoxia-Inducible Factors in Regulating Right Ventricular Function and Remodeling during Chronic Hypoxia-induced Pulmonary Hypertension.Am J Respir Cell Mol Biol. 2020 Nov;63(5):652-664. doi: 10.1165/rcmb.2020-0023OC. Am J Respir Cell Mol Biol. 2020. PMID: 32692928 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical